Alpha-v beta-3

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

αVβ3 is a type of integrin that is a receptor for vitronectin.[1] It consists of two components, integrin alpha V and integrin beta 3 (CD61), and is expressed by platelets. Furthermore, it is a receptor for phagocytosis on macrophages or dendritic cells.[2]

As a drug target[edit]

Integrin αVβ3 is potential drug target because abnormal expression of v3 is linked to the development and progression of various diseases.[3]

Inhibitors like etaracizumab may be used as antiangiogenics.[4]

One novel protein (ProAgio) has been designed to bind at an unusual site, and then induces apoptosis by recruiting caspase 8.[3]

See also[edit]

References[edit]

  1. ^ Hermann P, Armant M, Brown E, Rubio M, Ishihara H, Ulrich D, Caspary RG, Lindberg FP, Armitage R, Maliszewski C, Delespesse G, Sarfati M (February 1999). "The vitronectin receptor and its associated CD47 molecule mediates proinflammatory cytokine synthesis in human monocytes by interaction with soluble CD23". The Journal of Cell Biology. 144 (4): 767–75. doi:10.1083/jcb.144.4.767. PMC 2132927. PMID 10037797.
  2. ^ Yamaguchi H, Takagi J, Miyamae T, Yokota S, Fujimoto T, Nakamura S, Ohshima S, Naka T, Nagata S (May 2008). "Milk fat globule EGF factor 8 in the serum of human patients of systemic lupus erythematosus". Journal of Leukocyte Biology. 83 (5): 1300–7. doi:10.1189/jlb.1107730. PMID 18303131.
  3. ^ a b Novel Protein Agent Targets Cancer and Host of Other Diseases. June 2016
  4. ^ Santulli G, Basilicata MF, De Simone M, Del Giudice C, Anastasio A, Sorriento D, Saviano M, Del Gatto A, Trimarco B, Pedone C, Zaccaro L, Iaccarino G (January 2011). "Evaluation of the anti-angiogenic properties of the new selective αVβ3 integrin antagonist RGDechiHCit". Journal of Translational Medicine. 9 (1): 7. doi:10.1186/1479-5876-9-7. PMID 21232121.

External links[edit]